Saint Louis University

City University of New York

National and Kapodistrian University of Athens

John Edwin Tavis

Ryan Murelli

Marvin Jay Meyers

Lynda Anne Morrison

Amelia Pinto

James Brien

Maureen J Donlin

Rajeev Aurora

Grigoris Zoidis

Yuan Hu

Ryan P Murelli

The present disclosure provides inhibitors of bunyavirus of the formula: wherein the variables are defined herein. These inhibitors may be used to treat an infection of Rift Valley phlebovirus, hantavirus, and La Crosse virus, or Crimean-Congo Hemorrhagic fever.

Inhibitors ofand uses thereof

Inhibitors of Bunyaviridae and uses thereof

The present disclosure relates to inhibitors of herpesvirus nucleic acid metabolism and inhibitors of Hepatitis B virus. Also provided are methods of treatment using these agents.

Hydroxylated tropolone inhibitors of nucleotidyl transferases in herpesvirus and Hepatitis B and uses therefor

The present disclosure relates to identification of inhibitors of hepatitis and herpesvirus replication including compounds of the formula: wherein the variables are as defined herein. Also provided are methods of treatment using agents so identified.

Inhibitors of nucleotidyl transferases and uses in herpes and hepatitis viral infections therefor

The present disclosure provides compounds of the formula (I), (II), (III), wherein the variables are as defined herein for use in the treatment of fungal infections. In some embodiments, the fungal infection is an infection offungus. Also provided herein are compositions comprising a compound of formula I, II, or III and a second anti-fungal agent. 

Anti-fungal compounds

The present invention involves identification of inhibitors of herpesvirus nucleic acid metabolism. Also provided are methods of treatment using agents identified.

Inhibitors of HSV nucleotidyl transferases and uses therefor

Provided herein are methods for the obtention of an active HBV RNaseH preparation and its use in screening methods to identify potential inhibitors of the enzyme for possible use as therapeutic agents. Also provided are methods of treatment using agents identified according to the screen.

HBV RNAse H purification and enzyme inhibitors

Methods of identifying targets for designing a therapeutic agent are disclosed. These methods comprise: determining an amino acid sequence of one or more polypeptides of each isolate of a plurality of isolates of a biological system; identifying covariance pairs of amino acid residues; establishing a network comprising the covariance pairs; and identifying one or more hub residue positions, wherein a hub residue position comprises a target for designing a therapeutic agent if the hub residue position has a rank order in the 40percentile or greater. In other aspects, methods are disclosed for selecting a therapy for an infectious disorder. In various configurations, these methods comprise: determining amino acids occupying a plurality of diagnostic amino acid residue positions comprised by one or more polypeptides encoded by an infectious agent infecting a subject; and assigning the infectious agent infecting the subject to one covariance network selected from a plurality of covariance networks, wherein each network comprises a unique rank order of hubs with respect to the other networks, and whereby the therapy is selected on the basis of the covariance network assignment.

Growing community of inventors

Kirkwood, MO, United States of America

John Edwin Tavis